This article provides a comprehensive overview of the clinical characteristics of patients with KRAS mutations, outcomes, and ongoing clinical trials in advanced tumors with these mutations, with special consideration of NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.